/
Oncology
Advanced Cancer
54
Pipeline Programs↗
58
Active Trials↗
72
Companies Involved↗
Advanced Cancer is a moderately active landscape with 54 programs across 72 companies. The most active players are TORL Biotherapeutics, LLC, Volastra Therapeutics, Inc., Taiho Oncology, Inc.. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical6
Phase 128
Phase 219
Phase 31
Approved
No programs
Analysis
Modality Breakdown
87%
Small molecule
45 of 52 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 52 classified programs, each share of the total. Modality classified for 98% of 54 pipeline programs.
Analysis
Trial Status
385
clinical trials
Completed246 · 64%
Terminated58 · 15%
Recruiting27 · 7%
Active, not recruiting24 · 6%
Withdrawn12 · 3%
Unknown status9 · 2%
Other9 · 2%
Clinical Trials
Trial Activity
385 trials
Page 1 of 26
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)